# Comparison of Medications used for Smoking Cessation

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindications</th>
<th>Adverse Effects**</th>
<th>Dosage</th>
<th>Onset/Duration</th>
<th>Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nicotine Replacement Therapy (NRT)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nicotine Patch</strong>&lt;br&gt;(Nicoderm®, Habitrol®, other pharmacy store brands)&lt;br&gt;7 mg, 14 mg, 21 mg per 24 hours&lt;br&gt;Average S3-S4/day&lt;br&gt;No prescription required</td>
<td>All NRT Products: - Avoid during immediate post-myocardial infarction period, angina (severe or worsening), life-threatening arrhythmias - Uncontrolled hypertension - Recent stroke - Severe kidney/ liver disease - Pregnancy &amp; lactation - Allergy to nicotine - Non-smokers</td>
<td>**Patients are to stop smoking while using **&lt;br&gt;Heavy smokers &gt; 20/day:&lt;br&gt;One strategy:&lt;br&gt;21 mg/day x 6 wk, 14 mg/day x 2 wk, 7 mg/day x 2 wk.&lt;br&gt;Light smokers, heart disease or &lt; 45 kg:&lt;br&gt;One strategy:&lt;br&gt;14 mg/day x 6 wk, 7 mg/day x 2 – 4 wk&lt;br&gt;Titrination schedule should be personalized. Rotate patch site daily to avoid skin irritation&lt;br&gt;Wear patch for 16-24 hours&lt;br&gt;Never cut patch</td>
<td>Onset of action (Tmax): - Patch: 6-8 hours (slow) - Gum/Lozenge/Inhaler: 20-60 min (intermediate) - Oral spray: 1 min (fast) - Intranasal spray: 5-20 min (fast)</td>
<td>Duration of therapy: Up to 12 weeks or longer if needed. Do not use for &gt; 6 months without consulting physician. Typically, gradual withdrawal with personalized titration schedule and duration is recommended.</td>
<td>Smokers:&lt;br&gt;Nicotine itself does not impact hepatic enzymes and is not subject to cytochrome P-450 interactions. Tobacco smoke however produces polycyclic aromatic hydrocarbons (PAHs) which are potent inducers of CYP1A1, 1A2, and possibly 2E1. Smokers may require increased doses of substrate drugs. In contrast, when smoking is discontinued, the substrate drug may require a dosage decrease over a period of several days. Some authors have suggested a 10% daily-dose reduction over 4 days for substrates that have a narrow therapeutic range: (14,15) CYP1A1, 1A2 substrates: Theophylline Caffeine Cilazapam Olanzapine Fluvoxamine Tacrine TCAs (partial substrate) Nicotine: Nicotine is metabolized via CYP2A6, but is not an inducer or inhibitor of CYP450 isoenzymes. (16) There are no anticipated kinetic interactions. Monitor for treatment emergent hypertension when NRT is combined with bupropion.</td>
</tr>
<tr>
<td><strong>Nicotine Gum</strong>&lt;br&gt;(Nicorette®, other pharmacy store brands)&lt;br&gt;2 mg, 4 mg&lt;br&gt;Average S2-S8/day (6-25 pieces)&lt;br&gt;No prescription required</td>
<td>Nicotine can cause tachycardia and worsen underlying cardiac conditions. It may cause delayed healing of peptic ulcer disease and worsen vasospastic diseases.&lt;br&gt;Patch Only (in addition to above)&lt;br&gt;- Adhesive allergy&lt;br&gt;- Use during MRI – thermal burns reported due to aluminum lining.</td>
<td>Bite gum once or twice, then “park it” between cheek and gum. Wait and repeat, (one piece will last for approx 30 minutes). Chew slowly. Use 2 mg:&lt;br&gt; &lt; 25 cigarettes/day or smokes after first 30 minutes of waking.&lt;br&gt;Use 4 mg:&lt;br&gt; &gt; 25 cigarettes/day or smokes within 30 minutes of waking.&lt;br&gt;10–12 pieces/day chewed every 1–2 hour for first month. Maximum dose: 20 pieces/day&lt;br&gt;Titrination schedule should be personalized. Avoid acidic beverages (i.e. coffee, cola and citrus juices – prevent absorption)</td>
<td>Onset of action (Tmax): - Patch: 6-8 hours (slow) - Gum/Lozenge/Inhaler: 20-60 min (intermediate) - Oral spray: 1 min (fast) - Intranasal spray: 5-20 min (fast)</td>
<td>Duration of therapy: Up to 12 weeks or longer if needed. Do not use for &gt; 6 months without consulting physician. Typically, gradual withdrawal with personalized titration schedule and duration is recommended.</td>
<td>Smokers:&lt;br&gt;Nicotine itself does not impact hepatic enzymes and is not subject to cytochrome P-450 interactions. Tobacco smoke however produces polycyclic aromatic hydrocarbons (PAHs) which are potent inducers of CYP1A1, 1A2, and possibly 2E1. Smokers may require increased doses of substrate drugs. In contrast, when smoking is discontinued, the substrate drug may require a dosage decrease over a period of several days. Some authors have suggested a 10% daily-dose reduction over 4 days for substrates that have a narrow therapeutic range: (14,15) CYP1A1, 1A2 substrates: Theophylline Caffeine Cilazapam Olanzapine Fluvoxamine Tacrine TCAs (partial substrate) Nicotine: Nicotine is metabolized via CYP2A6, but is not an inducer or inhibitor of CYP450 isoenzymes. (16) There are no anticipated kinetic interactions. Monitor for treatment emergent hypertension when NRT is combined with bupropion.</td>
</tr>
<tr>
<td><strong>Nicotine Lozenge</strong>&lt;br&gt;(Nicorette® 2 mg, 4 mg; Thrive® 1 mg, 2 mg)&lt;br&gt;Average S4-S10/day (6-15 lozenges)&lt;br&gt;No prescription required</td>
<td>Nicorette:&lt;br&gt;Use 2mg:&lt;br&gt;smokes after first 30 minutes of waking.&lt;br&gt;Use 4mg:&lt;br&gt;smokes within 30 minutes of waking.&lt;br&gt;Slowly dissolve 1 lozenge in mouth, moving side to side over 20-30 minutes. Typically use 1 lozenge every 1-2 hours for 6 weeks, then every 2-4 hours for 3 weeks, then every 4-8 hours for 3 weeks. Maximum dose 15 lozenges/dayx2mg lozenges. Do not chew or swallow whole. Titration schedule should be personalized. Avoid eating or drinking 15 minutes before or while using the lozenge.</td>
<td>Onset of action (Tmax): - Patch: 6-8 hours (slow) - Gum/Lozenge/Inhaler: 20-60 min (intermediate) - Oral spray: 1 min (fast) - Intranasal spray: 5-20 min (fast)</td>
<td>Duration of therapy: Up to 12 weeks or longer if needed. Do not use for &gt; 6 months without consulting physician. Typically, gradual withdrawal with personalized titration schedule and duration is recommended.</td>
<td>Smokers:&lt;br&gt;Nicotine itself does not impact hepatic enzymes and is not subject to cytochrome P-450 interactions. Tobacco smoke however produces polycyclic aromatic hydrocarbons (PAHs) which are potent inducers of CYP1A1, 1A2, and possibly 2E1. Smokers may require increased doses of substrate drugs. In contrast, when smoking is discontinued, the substrate drug may require a dosage decrease over a period of several days. Some authors have suggested a 10% daily-dose reduction over 4 days for substrates that have a narrow therapeutic range: (14,15) CYP1A1, 1A2 substrates: Theophylline Caffeine Cilazapam Olanzapine Fluvoxamine Tacrine TCAs (partial substrate) Nicotine: Nicotine is metabolized via CYP2A6, but is not an inducer or inhibitor of CYP450 isoenzymes. (16) There are no anticipated kinetic interactions. Monitor for treatment emergent hypertension when NRT is combined with bupropion.</td>
<td></td>
</tr>
<tr>
<td><strong>Nicotine Inhaler</strong>&lt;br&gt;(Nicorette® Inhaler)&lt;br&gt;Usual dose: 6 – 12 cartridges/day by frequent continuous puffing over 5–20 minutes. Inhale as needed.</td>
<td>Usual dose: 6 – 12 cartridges/day by frequent continuous puffing over 5–20 minutes. Inhale as needed.</td>
<td>Onset of action (Tmax): - Patch: 6-8 hours (slow) - Gum/Lozenge/Inhaler: 20-60 min (intermediate) - Oral spray: 1 min (fast) - Intranasal spray: 5-20 min (fast)</td>
<td>Duration of therapy: Up to 12 weeks or longer if needed. Do not use for &gt; 6 months without consulting physician. Typically, gradual withdrawal with personalized titration schedule and duration is recommended.</td>
<td>Smokers:&lt;br&gt;Nicotine itself does not impact hepatic enzymes and is not subject to cytochrome P-450 interactions. Tobacco smoke however produces polycyclic aromatic hydrocarbons (PAHs) which are potent inducers of CYP1A1, 1A2, and possibly 2E1. Smokers may require increased doses of substrate drugs. In contrast, when smoking is discontinued, the substrate drug may require a dosage decrease over a period of several days. Some authors have suggested a 10% daily-dose reduction over 4 days for substrates that have a narrow therapeutic range: (14,15) CYP1A1, 1A2 substrates: Theophylline Caffeine Cilazapam Olanzapine Fluvoxamine Tacrine TCAs (partial substrate) Nicotine: Nicotine is metabolized via CYP2A6, but is not an inducer or inhibitor of CYP450 isoenzymes. (16) There are no anticipated kinetic interactions. Monitor for treatment emergent hypertension when NRT is combined with bupropion.</td>
<td></td>
</tr>
</tbody>
</table>
## Comparison of Medications used for Smoking Cessation

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindications</th>
<th>Adverse Effects**</th>
<th>Dosage</th>
<th>Onset/Duration</th>
<th>Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicotine Oral Spray</td>
<td></td>
<td></td>
<td></td>
<td>1-2 sprays into the mouth when patient would normally smoke a cigarette or have cravings to smoke. Use one spray first and if cravings do not disappear within a few minutes use the second spray. If 2 sprays are required, future doses may be delivered as 2 consecutive sprays. For most smokers this means about 1 or 2 sprays every 30 minutes to 1 hour. The maximum dose is 2 sprays at a time, 4 sprays per hour and 64 sprays per day.</td>
<td>1-2 doses intranasally (2-4 sprays) /hour; maximum 5 doses (10 sprays) /per hour and 40 doses (80 sprays) /per day. Use a minimum of 8 doses/day for efficacy. 0.5 mg nicotine per spray 1.0 mg nicotine per dose (2 sprays, one spray per nostril)</td>
</tr>
<tr>
<td>Nicotine Nasal Spray</td>
<td></td>
<td></td>
<td></td>
<td>1-2 doses intranasally (2-4 sprays) /hour; maximum 5 doses (10 sprays) /per hour and 40 doses (80 sprays) /per day. Use a minimum of 8 doses/day for efficacy. 0.5 mg nicotine per spray 1.0 mg nicotine per dose (2 sprays, one spray per nostril)</td>
<td></td>
</tr>
<tr>
<td>Other Drugs</td>
<td></td>
<td></td>
<td></td>
<td>1-2 doses intranasally (2-4 sprays) /hour; maximum 5 doses (10 sprays) /per hour and 40 doses (80 sprays) /per day. Use a minimum of 8 doses/day for efficacy. 0.5 mg nicotine per spray 1.0 mg nicotine per dose (2 sprays, one spray per nostril)</td>
<td></td>
</tr>
<tr>
<td>Bupropion SR (Zyban®)</td>
<td>Not recommended for those at high risk of seizures or those who have a seizure disorder.</td>
<td>- Agitation type events with self-harm. - Anorexia, nausea - Xerostomia - Tremor - Tachycardia - Dizziness - Headache - Insomnia - Agitation, Anxiety - Hallucinations - Seizures (at higher than recommended doses) - Hypotension</td>
<td>150 mg once daily x 3 days, then 150 mg twice daily (minimum 8 hr dosing interval; take the 2nd dose by early evening to minimize insomnia) Initiate while still smoking Quit smoking after 7 – 14 days of therapy Max total daily dose: 300 mg Max single dose: 150 mg Do not chew, divide or crush tablets</td>
<td>7 – 12 weeks, or longer if necessary Discontinue current treatment course if patient not abstinent by 7th wk of therapy. Maintenance (prevention of relapse) 300 mg/day for up to 1 year on individual basis Contraindicated with MAO inhibitors and thioridazine. Caution with levodopa and amantadine (increased CNS side-effects). (12) CYP2B6 substrate (metabolized to active hydroxybupropion); CYP2D6 inhibitor. (12) -Caution with drugs that lower seizure threshold (i.e. antipsychotics, antidepressants, theophylline, systemic steroids, etc.) (12) - CYP2B6 inhibitors or inducers may increase or decrease bupropion concentrations, respectively. - Potent inducers of various CYPs may also decrease bupropion concentrations (i.e. ritampin, carbamazepine, phenytoin, phenobarbital), Antiretrovirals (AVRs):</td>
<td>150 mg once daily x 3 days, then 150 mg twice daily (minimum 8 hr dosing interval; take the 2nd dose by early evening to minimize insomnia) Initiate while still smoking Quit smoking after 7 – 14 days of therapy Max total daily dose: 300 mg Max single dose: 150 mg Do not chew, divide or crush tablets</td>
</tr>
</tbody>
</table>
## Comparison of Medications used for Smoking Cessation

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindications</th>
<th>Adverse Effects**</th>
<th>Dosage</th>
<th>Onset/Duration</th>
<th>Interactions</th>
</tr>
</thead>
</table>
| Bupropion SR & Nicotine Transdermal System (Patch) Combination | Caution in patients with hypertension  
See Individual Agents | Initiate while still smoking: Bupropion 150 mg daily X 3 days, then 2 times daily (minimum 8 hr dosing interval; take the 2nd dose by early evening to minimize insomnia). Add nicotine patch to bupropion after 1 week of stop smoking. 21 mg/d x 7 wk, 14 mg/d x 1 wk then 7 mg/d x 1 wk. Taper patch during week 8 and 9. | 10 – 12 weeks, or longer if necessary | See Individual Agents  
Monitor for treatment emergent hypertension when NRT is combined with bupropion. | -Ritonavir, boosted ARVs: in vitro data suggest an increase in bupropion concentrations. (17) However, in vivo up to 57% decrease AUC bupropion is seen, depending on dose and duration of ritonavir therapy. May require an increase in bupropion dosage. (18-20)  
-Nelfinavir & Efavirenz: in vitro data suggest an increase in bupropion concentrations due to CYP2B6 inhibition. (17) One case series reported no increased episodes of seizures with either nelfinavir, ritonavir or efavirenz. (21) One study with efavirenz showed a 55% decrease AUC of bupropion. (22) May require an increase in bupropion dosage when combined with efavirenz.  
Bupropion may increase the levels of CYP2D6 substrates. Caution is warranted; a decreased dosage of the substrate drug may be required (i.e. antidepressants, antipsychotics, beta-blockers, type 1C antiarrhythmics). (12) |
| Varenicline (Champix®) | - Use in pregnancy and lactation not recommended  
- Use cautiously in those with schizophrenia, bipolar disorder or another major depressive disorder.  
- Use cautiously in those with kidney disease. Dosage adjustment required if the creatinine clearance is < 30 mL/minute.  
- Nausea  
- Constipation, flatulence  
- Xerostomia  
- Insomnia  
- Abnormal dreams (vivid)  
- Headache  
- Agitation, depression, suicidal thoughts, changes in behavior, worsening of pre-existing psychiatric disorders in patients with or without psychiatric disorder  
Varenicline 0.5 mg once daily for 3 days, then 0.5 mg twice daily for 4 days, then 0.5-1 mg twice daily for 11 weeks (interval of at least 6 hours between doses). If successfully quits after 12 weeks may continue for additional 12 weeks. If still smoking after 12 weeks stop drug and reassess contributing factors to smoking. Take with food and water to minimize nausea. Initiate while still smoking. Quit smoking after 7-14 days of therapy. | 12 weeks or longer if necessary | Not hepatically metabolized. Mainly excreted unchanged in the urine. No known clinically significant interactions. (13) Nicotine transdermal & varenicline may result in increased side-effects (i.e. nausea, headache, dizziness, and fatigue)  
In patients with severe renal impairment, varenicline may result in severe worsening of pre-existing psychiatric disorders. |
### Comparison of Medications used for Smoking Cessation

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindications</th>
<th>Adverse Effects**</th>
<th>Dosage</th>
<th>Onset/Duration</th>
<th>Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Not studied in the following populations; safety and efficacy data is lacking and caution is warranted (psychiatric disorders, pediatrics, epilepsy, gastrointestinal disease such as irritable bowel syndrome, heart disease, COPD, chemotherapy, uncontrolled hypertension, controlled diabetes).</td>
<td>disorders (Black Box Warning)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** Note: Smoking cessation and resulting nicotine withdrawal may mimic certain adverse effects of smoking cessation medications. Symptoms of nicotine withdrawal may include: cravings, depression, insomnia, irritability, anxiety, nervousness, drowsiness, increased appetite & weight gain. Nicotine toxicity is characterized by: nausea, salivation, abdominal pain, vomiting, diarrhea, diaphoresis, flushing, dizziness, confusion, palpitations, etc.

### References:

6. Selby P. Psychiatric Disorders: Smoking Cessation. June 2007, e-CPS (Compendium of Pharmaceuticals and Specialties). Available: [https://www.e-therapeutics.ca/wps/myportal/ut/p/_s.7_0_A/7_0_CL/cmd/acd/.ar/sa.DisplayContent/.c/6_0_6A/.ce/7_0_2U0/.p/5_0_27U/.d/1?PC_7_0_2U0_searchTerm=smoking&PC_7_0_2U0_value=e0042&PC_7_0_2U0_title=Psychiatric+Disorders%3A+Smoking+Cessation#7_0_2U0](https://www.e-therapeutics.ca/wps/myportal/ut/p/_s.7_0_A/7_0_CL/cmd/acd/.ar/sa.DisplayContent/.c/6_0_6A/.ce/7_0_2U0/.p/5_0_27U/.d/1?PC_7_0_2U0_searchTerm=smoking&PC_7_0_2U0_value=e0042&PC_7_0_2U0_title=Psychiatric+Disorders%3A+Smoking+Cessation#7_0_2U0) (Accessed 1 Sept 2009).
21. Selby P. Psychiatric Disorders: Smoking Cessation. June 2007, e-CPS (Compendium of Pharmaceuticals and Specialties). Available: [https://www.e-therapeutics.ca/wps/myportal/ut/p/_s.7_0_A/7_0_CL/cmd/acd/.ar/sa.DisplayContent/.c/6_0_6A/.ce/7_0_2U0/.p/5_0_27U/.d/1?PC_7_0_2U0_searchTerm=smoking&PC_7_0_2U0_value=e0042&PC_7_0_2U0_title=Psychiatric+Disorders%3A+Smoking+Cessation#7_0_2U0](https://www.e-therapeutics.ca/wps/myportal/ut/p/_s.7_0_A/7_0_CL/cmd/acd/.ar/sa.DisplayContent/.c/6_0_6A/.ce/7_0_2U0/.p/5_0_27U/.d/1?PC_7_0_2U0_searchTerm=smoking&PC_7_0_2U0_value=e0042&PC_7_0_2U0_title=Psychiatric+Disorders%3A+Smoking+Cessation#7_0_2U0) (Accessed 1 Sept 2009).

Alberta Health Services ASSUMES NO LIABILITY FOR THE USE OF THIS TEACHING SHEET

Reprinted with permission from Drug Information Services, Alberta Health Services.
Prepared by Chelsey Cabaj, BScPharm and Michelle Foisy, PharmD, Alberta Health Services – Pharmacy Services (Edmonton area)
Last Revision by Kim Gunderson, BScPharm, Rexall Outpatient Pharmacy, Royal Alexandra Hospital, Edmonton, AB October 2013